About: Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals
Creator	Wetzke, Martin Behrens, Georg Tran, Anh Cossmann, Anne Ernst, Diana Förster, Reinhold Jablonka, Alexandra Pink, Isabell Schulte, Bianca Stankov, Metodi Streeck, Hendrik Witte, Torsten Behrens, Boeck, Anna-Lena Bosnjak, Berislav Dopfer, Christian Georg, M Graalmann, Theresa Happle, Christine Horke, Alexander Kayser, Moritz Scharff, Anna Thiele, Thea Willenzon, Stefanie
Source	MedRxiv
abstract	Background: Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the COVID-19 pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods: In a large German university hospital, we performed weekly questionnaire assessments and anti-SARS-CoV-2 IgG measurements with various commercial tests, a novel surrogate virus neutralization test, and a neutralization assay using live SARS-CoV-2. Results: From baseline to week six, n=1,080 screening measurements for anti-SARS CoV-2 (S1) IgG from n=217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4 % in week six, p<0.001). In sera of convalescent PCR-confirmed COVID-19 patients, we measured high anti-SARS-CoV-2 IgG levels, obtained highly concordant results from ELISAs using e.g. the S1 spike protein domain and the nucleocapsid protein (NCP) as targets, and confirmed antiviral neutralization. However, in HCP the cumulative incidence for anti-SARS-CoV-2 (S1) IgG was 1.86% for positive and 0.93% for equivocal positive results over the six week study period. Except for one HCP, none of the eight initial positive results were confirmed by alternative serology tests or showed in vitro neutralization against live SARS CoV-2. The only true seroconversion occurred without symptoms and mounted strong functional humoral immunity. Thus, the confirmed cumulative incidence for neutralizing anti-SARS-CoV-2 IgG was 0.47%. Conclusion: When assessing anti-SARS-CoV-2 immune status in individuals with low pre-test probability, we suggest confirming positive results from single measurements by alternative serology tests or functional assays. Our data highlight the need for a methodical serology screening approach in regions with low SARS-CoV-2 infection rates.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1101/2020.08.06.20169250
has license	medrxiv
sha1sum (hex)	7d56a651ea58be717505a850c08b621641b9b30e
schema:url	https://doi.org/10.1101/2020.08.06.20169250
resource representing a document's title	Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals
resource representing a document's body	covid:7d56a651ea58be717505a850c08b621641b9b30e#body_text
is schema:about of	named entity 'Contact' named entity 'SUSPECTED' named entity 'SEROCONVERSION' named entity 'prevalence' named entity 'seroconversion' named entity 'infection' named entity 'COVID' named entity 'COVID-19 pandemic' named entity 'seroconversion' named entity 'Serology testing' named entity 'serology' named entity 'SARS-CoV-2' named entity 'IgA' named entity 'receptor binding domain' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'IgG' named entity 'IgG' named entity 'infection' named entity 'HCP' named entity 'Germany' named entity '37°C' named entity 'Sanofi-Aventis' named entity 'pre-test probability' named entity 'HCP' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Severe Acute Respiratory Syndrome Coronavirus 2' named entity 'infection' named entity 'medRxiv' named entity 'IgG' named entity 'humoral' named entity 'virus' named entity 'Heinsberg' named entity 'SARS' named entity 'Serology' named entity 'polymerase chain reaction' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'Wuhan' named entity 'antibody' named entity 'nosocomial' named entity 'IgG' named entity 'COVID' named entity 'Germany' named entity 'health status' named entity 'community-acquired' named entity 'infection' named entity 'SARS CoV' named entity 'IgG' named entity 'Germany' named entity 'Germany' named entity 'Boehringer Ingelheim' named entity 'SARS-CoV-2' named entity 'serological testing' named entity 'seroconversion' named entity 'Gilead' named entity 'Germany' named entity 'ELISAs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software